Format
Sort by

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 247

1.

Gerosuppression by pan-mTOR inhibitors.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2016 Dec 30;8(12):3535-3551. doi: 10.18632/aging.101155.

2.

Dual mTORC1/C2 inhibitors suppress cellular geroconversion (a senescence program).

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Oncotarget. 2015 Sep 15;6(27):23238-48.

3.

Energy excess is the main cause of accelerated aging of mammals.

Biliński T, Paszkiewicz T, Zadrag-Tecza R.

Oncotarget. 2015 May 30;6(15):12909-19.

4.

Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats.

Lesovaya EA, Kirsanov KI, Antoshina EE, Trukhanova LS, Gorkova TG, Shipaeva EV, Salimov RM, Belitsky GA, Blagosklonny MV, Yakubovskaya MG, Chernova OB.

Oncotarget. 2015;6(12):9718-27.

5.

Rejuvenating immunity: "anti-aging drug today" eight years later.

Blagosklonny MV.

Oncotarget. 2015 Aug 14;6(23):19405-12.

6.

Tumor promoter-induced cellular senescence: cell cycle arrest followed by geroconversion.

Leontieva OV, Blagosklonny MV.

Oncotarget. 2014 Dec 30;5(24):12715-27.

7.

Gerosuppression in confluent cells.

Leontieva OV, Blagosklonny MV.

Aging (Albany NY). 2014 Dec;6(12):1010-8.

8.

Fasting levels of hepatic p-S6 are increased in old mice.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(17):2656-9. doi: 10.4161/15384101.2014.949150.

9.

Comparison of rapamycin schedules in mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Cell Cycle. 2014;13(21):3350-6. doi: 10.4161/15384101.2014.970491.

10.

Geroconversion: irreversible step to cellular senescence.

Blagosklonny MV.

Cell Cycle. 2014;13(23):3628-35. doi: 10.4161/15384101.2014.985507. Review.

11.

Koschei the immortal and anti-aging drugs.

Blagosklonny MV.

Cell Death Dis. 2014 Dec 4;5:e1552. doi: 10.1038/cddis.2014.520. Review.

12.

Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.

Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D, Alnemri ES, Altucci L, Andrews D, Annicchiarico-Petruzzelli M, Baehrecke EH, Bazan NG, Bertrand MJ, Bianchi K, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C, Campanella M, Candi E, Cecconi F, Chan FK, Chandel NS, Cheng EH, Chipuk JE, Cidlowski JA, Ciechanover A, Dawson TM, Dawson VL, De Laurenzi V, De Maria R, Debatin KM, Di Daniele N, Dixit VM, Dynlacht BD, El-Deiry WS, Fimia GM, Flavell RA, Fulda S, Garrido C, Gougeon ML, Green DR, Gronemeyer H, Hajnoczky G, Hardwick JM, Hengartner MO, Ichijo H, Joseph B, Jost PJ, Kaufmann T, Kepp O, Klionsky DJ, Knight RA, Kumar S, Lemasters JJ, Levine B, Linkermann A, Lipton SA, Lockshin RA, López-Otín C, Lugli E, Madeo F, Malorni W, Marine JC, Martin SJ, Martinou JC, Medema JP, Meier P, Melino S, Mizushima N, Moll U, Muñoz-Pinedo C, Nuñez G, Oberst A, Panaretakis T, Penninger JM, Peter ME, Piacentini M, Pinton P, Prehn JH, Puthalakath H, Rabinovich GA, Ravichandran KS, Rizzuto R, Rodrigues CM, Rubinsztein DC, Rudel T, Shi Y, Simon HU, Stockwell BR, Szabadkai G, Tait SW, Tang HL, Tavernarakis N, Tsujimoto Y, Vanden Berghe T, Vandenabeele P, Villunger A, Wagner EF, Walczak H, White E, Wood WG, Yuan J, Zakeri Z, Zhivotovsky B, Melino G, Kroemer G.

Cell Death Differ. 2015 Jan;22(1):58-73. doi: 10.1038/cdd.2014.137. Review.

13.

Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8832-7. doi: 10.1073/pnas.1405723111.

14.

Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.

Leontieva OV, Demidenko ZN, Blagosklonny MV.

Cell Death Dis. 2014 May 8;5:e1214. doi: 10.1038/cddis.2014.178.

15.

Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet.

Leontieva OV, Paszkiewicz GM, Blagosklonny MV.

Aging Cell. 2014 Aug;13(4):616-22. doi: 10.1111/acel.12211.

16.

Immunosuppressants in cancer prevention and therapy.

Blagosklonny MV.

Oncoimmunology. 2013 Dec 1;2(12):e26961. Review.

17.

Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Popovich IG, Anisimov VN, Zabezhinski MA, Semenchenko AV, Tyndyk ML, Yurova MN, Blagosklonny MV.

Cancer Biol Ther. 2014 May;15(5):586-92. doi: 10.4161/cbt.28164.

18.

M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue.

Leontieva OV, Blagosklonny MV.

Cell Cycle. 2014;13(4):509-15. doi: 10.4161/cc.27973.

PMID:
24496328
19.

Selective anti-cancer agents as anti-aging drugs.

Blagosklonny MV.

Cancer Biol Ther. 2013 Dec;14(12):1092-7. doi: 10.4161/cbt.27350.

20.

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists.

Blagosklonny MV.

Cell Death Dis. 2013 Dec 12;4:e964. doi: 10.1038/cddis.2013.506. Review.

Items per page

Supplemental Content

Loading ...
Support Center